Heron Bay Capital Management Takes Position in Lantheus Holdings, Inc. $LNTH

Heron Bay Capital Management acquired a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 39,362 shares of the medical equipment provider’s stock, valued at approximately $4,367,000.

A number of other institutional investors and hedge funds have also bought and sold shares of LNTH. Keating Financial Advisory Services Inc. acquired a new position in Lantheus during the 2nd quarter valued at $404,000. Allworth Financial LP acquired a new stake in Lantheus in the 2nd quarter worth $49,000. Vise Technologies Inc. bought a new position in shares of Lantheus during the 2nd quarter worth about $503,000. Great Lakes Advisors LLC bought a new position in shares of Lantheus during the 2nd quarter worth about $4,069,000. Finally, Danske Bank A S bought a new position in shares of Lantheus during the 2nd quarter worth about $329,000. Institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on LNTH. The Goldman Sachs Group reiterated a “neutral” rating and issued a $94.00 target price on shares of Lantheus in a research note on Thursday, May 7th. TD Cowen lowered Lantheus from a “buy” rating to a “hold” rating and lowered their price target for the company from $110.00 to $102.50 in a research note on Monday, August 3rd. Wall Street Zen cut Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. William Blair set a $102.50 price objective on Lantheus in a research report on Monday, August 3rd. Finally, Weiss Ratings lowered Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, August 13th. Four analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $108.11.

Lantheus Stock Performance

Lantheus stock opened at $99.97 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89. The stock has a fifty day moving average price of $104.08 and a two-hundred day moving average price of $90.35. Lantheus Holdings, Inc. has a 52-week low of $49.67 and a 52-week high of $111.86. The firm has a market capitalization of $6.53 billion, a P/E ratio of 24.15 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The company had revenue of $388.18 million during the quarter, compared to analysts’ expectations of $363.23 million. During the same period last year, the business earned $1.57 earnings per share. The business’s revenue was up 2.7% on a year-over-year basis. As a group, analysts anticipate that Lantheus Holdings, Inc. will post 4.48 EPS for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.